DEPARTMENT OF THE ARMY Fort Detrick Frederick, Maryland

Similar documents
TO Approved for public release, distribution unlimited

THE INFLUENCE OF STREPTOCOCCUS ALLER- GEN AND STREPTOLYSIN 0 ON THE FORMA- TION OF ANTITETANUS IMMUNITY DISTRIBUTED BY:

Gye and Cramer (1919) found that the ionizable salts of calcium injected together with the washed spores of Cl. tetani or of certain

Calf pneumonia: Antibiotic Treatment and Study of Some Blood Immunological Parameters of the Natural Resistance

ENVIRACOR J-5 aids in the control of clinical signs associated with Escherichia coli (E. coli) mastitis

USA Product Label LINCOCIN. brand of lincomycin hydrochloride tablets. brand of lincomycin hydrochloride injection, USP. For Use in Animals Only

3.0 Treatment of Infection

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

= 0.5 mg. In vitro toxin neutralisation test based on haemolysis of sheep erythrocytes. For a full list of excipients, see section 6.1.

DTIC I., I, I 8 8. N LD Lfl 0. N. IELECTE FEB2 8 89D Gordon R. Dreesman HTLV III VIRUS ISOLATION STUDIES ANNUAL REPORT. October 30, 1987.

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

Doxycycline staph aureus

New Patient Information and Medical History Sheet

Simplicef is Used to Treat Animals with Skin Infections

About MRSA. MRSA (sometimes referred to as a superbug) stands for meticillin resistant Staphylococcus aureus.

Barriers to Intravenous Penicillin Use for Treatment of Nonmeningitis

THE GENERAL ASSEMBLY OF PENNSYLVANIA SENATE BILL REFERRED TO AGRICULTURE AND RURAL AFFAIRS, JANUARY 27, 2017 AN ACT

PRESCRIBED ANTIBIOTICS. By the right dose and frequency of antibiotics. Prescribed antibiotics are important.

Influences on tetanus immunization in

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Hendra virus: Important information for all horse owners. An update on Hendra virus The Hendra vaccine

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

B. PACKAGE LEAFLET 1

Abstract. Introduction

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

SUMMARY OF PRODUCT CHARACTERISTICS

BOARD OF SUPERVISORS BUSINESS MEETING ACTION ITEM

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

CAUTION Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

TREATMENT OF ANOESTRUS IN DAIRY CATTLE R. W. HEWETSON*

Summary of Product Characteristics

Q1. (a) Clostridium difficile is a bacterium that is present in the gut of up to 3% of healthy adults and 66% of healthy infants.

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/18

Antibiotic-resistant Staphylococcus aureus in dermatology and burn wards

European Public MRL assessment report (EPMAR)

Early Onset Neonatal Sepsis (EONS) A Gregory ST6 registrar at RHH

Pediatric Surgical Approach To Childhood Abscess: A Study From An Outpatient Facility

Author - Dr. Josie Traub-Dargatz

Summary of Product Characteristics

EUROPEAN REFERENCE LABORATORY (EU-RL) FOR BOVINE TUBERCULOSIS WORK-PROGRAMME PROPOSAL Version 2 VISAVET. Universidad Complutense de Madrid

Why Don t These Drugs Work Anymore? Biosciences in the 21 st Century Dr. Amber Rice October 28, 2013

Anti-infective Studies

Author of PGD: Adrian MacKenzie, Lead Pharmacist, Community Pharmacy.

Healthcare-associated Infections Annual Report December 2018

Cefazolin vs. Antistaphyloccal Penicillins: The Great Debate

Changing Trends and Issues in Canine and Feline Heartworm Infections

Use of a novel adjuvant to enhance the antibody response to vaccination against Staphylococcus aureus mastitis in dairy heifers.

BELIEFS AND PRACTICES OF PARENTS ON THE USE OF ANTIBIOTICS FOR THEIR CHILDREN WITH UPPER RESPIRATORY TRACT INFECTION

Clinical Policy: Linezolid (Zyvox) Reference Number: CP.PMN.27 Effective Date: Last Review Date: Line of Business: HIM*, Medicaid

SUMMARY OF PRODUCT CHARACTERISTICS. NUFLOR 300 mg/ml solution for injection for cattle and sheep

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process High Priority

S. ll IN THE SENATE OF THE UNITED STATES A BILL

ANTIBIOTICS USED FOR RESISTACE BACTERIA. 1. Vancomicin

General Approach to Infectious Diseases

Clinical Policy: Linezolid (Zyvox) Reference Number: CP.PMN.27 Effective Date: Last Review Date: Line of Business: Oregon Health Plan

Prophylactic antibiotic timing and dosage. Dr. Sanjeev Singh AIMS, Kochi

OIE Standards for: Animal identification and traceability Antimicrobials

17June2017. Parampal Deol, Ph.D, MBA Senior Director, R&D Microbiology North America

AMERICAN ACADEMY OF PEDIATRICS PROCEEDINGS. Report of a Round Table Discussion

EXCEDE Sterile Suspension

SUPPLY OF CHLORAMPHENICOL EYE DROPS 0.5% UNDER THE MINOR AILMENT SERVICE

Testimony of the Natural Resources Defense Council on Senate Bill 785

Mariana Grazing and Livestock Management Academy Livestock Health: Pinkeye, Bloat, and Foot Rot

SPREADSHEET MODELS FOR FOCUSING RESEARCH ON HIGH YIELD PREVENTION AND CONTROL STRATEGIES

Breastfeeding Challenges - Mastitis & Breast Abscess -

Comparison of Clindamycin, Erythromycin, and Methicillin in Streptococcal Infections in Monkeys

Indicated for the treatment of pruritus associated with allergic dermatitis and the clinical manifestations of atopic dermatitis in dogs.

SUPPLY OF CHLORAMPHENICOL EYE DROPS 0.5% UNDER THE MINOR AILMENT SERVICE

These recommendations were approved for use by the Pharmaceutical and Therapeutics Committee, RCWMCH on 1 February 2017.

RESULT OF STUDYING SOME ACUTE PHASE PROTEINS AND CORTISOL IN PREGNANT EWES

Federal Expert Select Agent Panel (FESAP) Deliberations

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Patients. Excludes paediatrics, neonates.

VET VIEWS from the University of California, Davis. Preventing Pinkeye in Your Herd

Antibiotic Resistance and Hospital-Acquired Infection Prof. Carl T. Bergstrom

A first-line treatment for ear infections in children with ear tubes*

Does history-taking help predict rabies diagnosis in dogs?

VETERINARY PRODUCT REGISTRATION

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Some observations on the penetration of antibiotics

Cellulitis. Assoc Prof Mark Thomas. Conference for General Practice Auckland Saturday 28 July 2018

ARCH-Vet. Summary 2013

Cercetări bacteriologice, epidemiologice şi serologice în bruceloza ovină ABSTRACT

ANTIBIOTIC RESISTANCE TRENDS IN CLINICAL BOVINE MASTITIS ABSTRACT

SUMMARY OF PRODUCT CHARACTERISTICS. Bottle of powder: Active substance: ceftiofur sodium mg equivalent to ceftiofur...

Overview. There are commonly found arrangements of bacteria based on their division. Spheres, Rods, Spirals

amoxycillin/clavulanate vs placebo in the prevention of infection after animal

SUMMARY OF PRODUCT CHARACTERISTICS. Cephacare flavour 50 mg tablets for cats and dogs. Excipients: For a full list of excipients, see section 6.1.

Evaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals

Finnzymes Oy. PathoProof Mastitis PCR Assay. Real time PCR based mastitis testing in milk monitoring programs

CLINICAL MASTITIS PERCEPTIONS OF KANSAS DAIRY PRODUCERS. J.R. Roberson 1

TO Approved for public release, distribution unlimited

Active Bacterial Core Surveillance Site and Epidemiologic Classification, United States, 2005a. Copyright restrictions may apply.

Department of Veterinary Medicine

Mrsa abscess and cellulitis

Animals & Reptiles (PA) LD P KER CHIPS. *** Variations

UNDERGRADUATE ACADEMIC STUDIES (Veterinary medicine 2013) UNIVERSITY OF NOVI SAD

Transcription:

b TRANSLATION NO. LO~m DATE: DDC AVAILABILITY NOTICE Qualified requestors may obtain copies of this document from DDC. This publication has been translated from the open literature and is available to the general public. Non-DOD agencies may purchase this publication from the Clearinghouse for Federal Scientific and Technical Information, U. S. Department of Commerce, Springfield, Va. Thi do~ '~c. 1kw pubic~ T- :-s twvn approvedl C%) sae &I;ts DEPARTMENT OF THE ARMY Fort Detrick Frederick, Maryland R-p.o'v, c# by 1h, CLEARINGHousE Io, %ederi -Scoenthfc & Tech-,,ja.% lnlor m~,,, Sprngfhold Va 22151

~~~SULAIMEI NOTICE THIS DOCUMENT IS BEST QUALITY AVAILABLE. THE COPY FURNISHED TO DTIC CONTAINED A SIGNIFICANT NUMBER OF PAGES WHICH DO NOT REPRODUCE LEGIBLY.

r I EXPERIENCE IN THE TREATMENT OF STAPHYLOCOCCAL DISEASES IN INFANTS BY USING STAPHYLOCOCCAL ANATOXIN [Following is the translation of an article by L. A. Rudneva, Lvov Scientific-Research Institute for Maternity and Childhood Protection (Director-Master of Medical Sciences L. Ya. Davydov), published in the Russian-language periodical Pediatriya (Pediatrics), 43:8-13, October 1964, It was submitted on 7 April 1964. Translation performed by Sp/7 Charles T. Ostertag, JrJ In recent years in our country and abroad a steady increase has been observed in the specific importance of staphylococcal diseases in the pathology of children in the first year of life (Yu. F. Dombrovskaya; P. A. Ponomareva; A. R. Shurinok; I. A. Shtern). Children come dowr with staphylococcal infections most often during the first 3 months of L.Le (Ye. I. Semonova). The increase in the resistance of staphylococci to antibiotics and sulfanilamides has created great difficulties in the treatment of staphylococcal diseases, and frequently complex therapy turns out to be ineffective. Besides this, antibiotics depress the immunological reactivity of an organism (human subject) (Kh. Kh. Planelyes and N. V. Chumachenko; N. I. Pokoziy; Yu. M. Mikhaylova), which also has an unfavorable influence on the results of treatment. Therefore, in the therapy of severe forms of staphylococcal infections = clinicians are resorting to the use of staphylococcal toxoid for the purpose of stimulating the specific immunological reactivity of the infant. At the present time staphylococcal toxoid is being used for the treatment of staphylococcal diseases in children. A. R. Shurinok, Ye. K. Yatsimirskaya and R. D. Nikolayev, and V. I. Nosovskaya observed a favorable influence on the recovery process following the administration of staphylococcal toxoid to sick children. One of the additional and reliable criteria of a positive influence of toxoid is the increase in the titer of staphylococcal antitoxin. In healthy babies the level of staphylococcal antitoxin in the blood, based on data from the literature, fluctuates from 0.25 to 2 AU. The content of staphylococcal antitoxin in the blood of young children during staphylococcal infections'and during treatment of this age group has not been ttudied sufficiently. The purpose of this work was the study of the effectiveness of staphylococcal toxoid for the treatment of babied with staphylococcal diseases.

Of these, 47 received staphy- The remaining 42 served as A total of 89 patients were observed. lococcal toxoid in the complex of medicines. a control. Prior to admission into the clinic the children were located in district and regional hospitals where they received 1-2 and more antibacterial preparations without noticeable success. The patients were hospitalized in various periods from the onset oi illness: During the ist week 16 children were admitted, in 2-4 weeks - 15, in 2-3 months - 16. In the control group 18 children were admitted in the let week of illness, 11, in the 2-4th week, and 13 in the 2-3rd month. Thus, there were no significant differences in the periods of hospitalization of the patients of both groups. The clinical characteristics of the sick children are presented in Table 1. Based on the indices presented in Table 1, both groups of children were basically the same. Based on the nature of the disease and the severity of the course both groups of children were also equivalent (Table 2). The treatment of the patients was complex (hygienic-dietetic regulation, vitamins, blood infusion, plasma, antibiotics, etc.). Along with the generally accepted therapy 47 of the children received native staphylococcal toxoid. The latter was injected together with Novocaine subcutaneously into the subscapular area. Different doses of toxoid %ere used. Thus, 20 children received the toxoid in increasing doses in accordance with the instructions of the N. F. Gamaleya Institute of Epidemiology and Microbiology. The sequence of administration was 0.1-0.3-0.5-0M7-1.0-1.2-1.5-1.7-2.0 ml with intervals of 3-5 days between injections. When using such a method of administration, especially with the injection of large doses (I ml and more), we observed in the children a reddening of the skin and a small induration at the site of administration of the toxoid. This lasted for 2-4 days. A noticeable general reaction was not observed. The other group of children (27) received the toxoid in smaller amounts, the maximum dose did not exceed 1 ml. Neither a local or general reaction was observed in the children when such a method was used. From the first days of treatment, unrest and apathy gradually disappeared in the patients, sleep and appetite improved, and the children began to gain weight. The general condition became satr-factory and thetemperature dropped to normal figures. Normalization of temperature was Nreached by the 25th day of treatment in 37 children of the let group, and by the 56th day in the remaining 10, while in the control group the tempera- 2

ture became normal during the first month of treatment in 25 children, and in 17 it took 70 days from the onset of treatment. Pyemic foci were liquidated in various periods. In 42 children of the first group they disappeared during the course of a month from the onset of treatment with staphylococcal toxoid, and in 2 patients - later. In 3 children, repeated waves of newly appearing purulent foci were observed in the second month of treatment. In 2 patients, this was due to an interrupted course of treatment with toxoid. In the 2nd group the pyemic foci disappeared in 23 children during the 1st month. In the remaining 18, repeated waves were often noted with the appearance of new purulent foci in the course of 2 months, and in only one was recovery not achieved. The periods for the improvement of the general condition and the disappearance of pyemic foci were reflected in the periods of recovery. In the Ist group 26 children recovered by the 30th day of their stay in the clinic, 18 children by the 50th day, and 3 children were discharged with some improvement. It should be noted that 7 recovered children were kept in the clinic up to 2k-3 months for reasons not connected with the disease. In the 2nd group only 15 children recovered by the 30th day, 22 by the 50th day, and the remaining 5 children - in later periods (on the 88th day). (All of these were discharged in a satisfactory condition, except 4 children, discharged with improvement and one child without improvement.) Changes in hematological indices also took place diversely. It was established that in the children of the 1st group the tendency for an increase in the number of erythrocytes was somewhat more expressed In comparison with the patients of the control group. No difference could be noticed in the increase in the content of hemoglobin among these groups of patients. An increased number cf leukocytes - from 14,000 up to 25,000 - was observed in 17 children of the 1st group. During the process of treatment normalization set in in 3 weeks in 15 of the patients. In the control group, of 23 children with the number of leukocytes ranging from 14,000 to 28,000, normalization set in during the same period in only 6 children. Consequently, in the 1st group the number of leukocytes became normal more rapidly than in the control group. In a large number of children of the 1st group an accelerated ESR was observed prior to treatment. This was lowered during the process of therapy. In one child it did not change, and in 2 patients it even increased by the end of their stay in the clinic. In the control group the accelerated ESR was also lowered under the influence of treatment, however the degree of lowering was less significant in comparison with the patients who received toxoid. Besides this, in a comparatively large number of patients (7 children), a speeding up of the ESR was noted by the end of the observation. 3

Consequently, as a resolt of using toxoid, an earlier and more noticeable lowering of the ESR was observed in the children. Apart from the clinical observation of the children a bacteriological invesligation of the pus and blood was performed. In the let group seekings from the pus of 40 children were made. Staphylococci were isolated in 39 cases. liis included 34 strains of aureus and 5 strains of albus. During the bacteri-logical investigation of the blood staphylococci were seededout in 10 children of the 47 investigated. Staphylococcus aureus was isolated in 3 cases, and S. albus in 7. In the 2nd (cntrol) group the seedings of pus was carried out on 12 children. Staphylocrcci were isolated in all cases. This included 10 of aureus and 2 of alb,,'- (-A-Ing -f HIocc' - - -Z roup staphylococci were seeded out in 15 children out of 42. In 14 cases Staphylococcus albus was isolated and in one case S. aureus. Thus, a total of 76 stra!ns of staphylococci were isolated. A study of the sensitivity of these strains to antibiotics was performed by the method of paper diagnostic discs. The majority of the strains of staphylococcus were resistant to biomycin, penicillin, streptomycin and Levomycetitr.. A sensitivity to erythromycin, colimycin and oxytetracycline was determined in only some of the strains. These investigations showed that the sensitivity of staphylococci to these antibiotics was more expressed. Thus, all the investigated strains were sensitive to colimycin and the greater majority to erythromycin and oxytetracycline. For the purpose of studying the imunological response of a child to the administration of staphylococcal toxoid we determined the content of staphylococcal antitoxin in the blood before and after the administration of the preparation. Prior to immunization 46 children were investigated, and after imunization - 33 children. It was established here that prior to the administration of the toxoid the amount of staphylococcal antitoxin fluctuated from 0.125 up to 2 AU. The average titer equaled 0.70k 0.078 AU. Following treatment, the content of antitoxin in the blood increased in all the children and fluctuated within 1-16 AlT. In the majority of children the titer was within the limits of 3-4 AU, and only in individual cases between 10-16 AU. The average titer of antitoxin equaled 3.351 0.49 AU. The content of antitoxin was also determined in the blood of 10 children in the control group after the treatment. In them the antibody level fluctuated within the limits of 0.25-2 AU and the average titer of antitoxin equaled 0.77t0.16 AU. Consequently, the clinical recovery of children in the control -roup wa not accompanied by an increase in the titers of antitoxin. Therefore,

the antibody titers in the children treated with the toxoid testifies to an increase in the specific immunological reactivity of the organism under the influence of toxoid. Since we used the staphylococcal toxoid in various doses, the amount of antitoxin in the blood was analyzed separately depending on the amount of the preparation administered (Table 3). It can be seen from the data in Table 3 that following the administratior, of various doses of staphylococcal toxoid we observed a statictically reliable increase in the level of antitoxin in the blood in the children. The use of larger doses of toxoid led to a more considerable accumulation of antitoxin. Conclusions 1. The use of staphylococcal toxoid in conjunction with other medicines exerted a favorable influence on the course and outcome of staphylococcal diseases in babies. 2. The administration of toxoid furthered a reduction in the period for recovery, a more rapid disappearance of pyemic foci and an earlier normaliza-ion of hematological indices. 3. The use of staphylococcal toxoid led to an increase in the specific immunological reactivity of the child. This was indicated by an increase in the titers of staphylococcal antitoxin in the blood. 4. Following the administration of native staphylococcal toxoid a noticeable local and general reaction was not observed. Literature Baklanova, V.F., Zvyaginiseva, S.G., Pediatriya, 1960, No. 3, page 13. Zubkova, V.L., and others, Balaban, V.G., Yeremenko, A.A., Zykova, O.L., Thesis of Reports of the Ard Conference of Pediatricians, Ukrainian SSR, B.N., 1961, p 68. Bogomez, T.A., Gink, R.A., Vopr. oxhr. mat., 1963, No. 5, p 7. Voskresenskiy, B.V., Dmitriyeva, A.I., Lebedeva, Z.I., ZhMEI, 1961, No. 1, p 33. Vygodchikov, C.V., Microbiology and Immunology of Staphylococcal Diseases, Moscow, 1950. Gorgiyev, T.A., Ketkev, G.F., Zaslavakaya, Ye. S., Xhiruruiya, 1962, No. 12, p 57. S

Grishchenko, Ye. M., In the book: Staphylococcal Diseases in Childhood and How to Combat Them, Kiev, 1963, p 64. Dombrovskaya, Yu. F., Trudy 7th All-Union Conference of Children's Doctors, Leningrad, 1959, p 96. Idem, Pediatriya, 1959, No. 1, p 5. Zvyagintseva, S.G., et al., Thesis of Reports of tfke 8th Session of Children's Doctors, Moscow, 1962, p 39. Kateyeva, G.F., Kazansk. med. zh., 1958, No. 2, p 94. Koroleva, N.I., Gribenik-, T.M., Agarkova, A.D. et al., Thesis of Reports of the 3rd Session of Pediatricians, Ukrainian SSR, B. M., 1961, p 63. Krasovskiy, V.V., Protopapov, A.N., Pediatriya, 1962, No. 9, p 7. Mikhaylova, Yu. M., Antibiotiki, 1960, No. 4, p 72. Nosovskaya, V.I., Pediatriya, 1963, No. 3, p 68. Planelyes, Kh. KI., Chumachenko, N.V., Antibiotiki, 1956, No. 1, p 25. Pokoziy, N.I., Antibiotiki, 1959, No. 4, p 85. Ponomareva, P.A., Trudy of the Sci. Session of the ANN USSR in Yerevan, Moscow, 1%0, p 146. Popova, P.P., ZhNEI, 1%3, No. 10, p 63. Baklanova, V.F. et al., Pediatriva, 1960, No. 3, p 13. Semenova, Ye. I., Peditriya, 1960, No. 3, p 8. Tur, A.F., Thesis of Reports of the 8th All-Union conference of Children's Doctors, Moscow, 1%2, p 5. Kh-skin, S.G., Yegorova, A.P. et al., Trudy of the 1st Conference of Obetetriciaas and Gynecologists, RSFSR, Leningrad, 1961, p 274. Chelniy, A.M., Titova, V.S., Zlatkina, S.A., Ilid, p 279. Chistovich, G.N., Pathogenesis of Staphylococcal Infections, Leningrad, 1961. Shtern, I.A., Pediatriva, 1960, No. 3, p 3. Shurinok, A.R., Thesis of Reports of the 3rd Congress of Pediatricians, Ukrainian 881, 1. H., 1%1, p 62. 6

Yusko, S.M., Ibid, p 65. Yatsimirskaya, Ye. K., Nikolayev, R.D., In the book: Staphylococcal Diseases in Children and How to Combat Them, Kiev, 1963, p 91. Viskott, A., Trudy of the 7th Conference of Childrens Doctors, Leningrad, 1959, p 113. 7

0 c1-00 C 0" o 1A81 I 'O TQ9AT I to 0 CDf bo oc 44. 0 MW;uM T0; 0 0 SAVp 9 MUXj3 0 ~UeOTIPP ~i om- I., xajqww1 ' go 04 4-,- ii 0 Lai-Q 1.-

Table 2 Clinical manifestations and the severity of the course of illness Group of patients Diagnosis Course r. I a) 0 H.H Received staphylococcal toxoid (1st group) 47 25 17 5 23 24 Control (2nd group) 42 30 12-19 23 Total 89 55 29 5 42 47 Table 3 Average titers of antitoxin in children who had received different doses of toxoid Dosage of toxoid Average titer of antitoxin (in AU) % prior to after inmunization iomunization ' 4J.,.,_ 0 0)4-' > Xt.VO4, M 14i.. 1 0 4) Large doses 20 0.86±-0.13 20 4.07'!0.83 3.80 more than 99 Small doses 26 0.57±0.03( 13 2.3 ±0.3 5.28 more than 99 9